Tenet Healthcare Corporation Stock Price and Value Analysis

Tenet Healthcare Corporation (NYSE:THC) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Tenet Healthcare Corporation to reach your target.

Target type

THC Free Cash Flow Trend

Free Cash Flow trendline for THC
Free Cash Flow trendline for Tenet Healthcare Corporation
CSV

Based on historical returns, we believe that Tenet Healthcare Corporation can grow its free cash at a rate of about 3%. That's positive!

AdvantagesDisadvantagesNeutral
  • This stock is available at a great discount!
  • This company is very stable.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the THC Numbers

THC Price
(Tenet Healthcare Corporation stock price per share)
$263.19
[?] THC Fair Price
(based on intrinsic value)
$332.57
[?] THC Safety Price (based on a variable margin of safety) $266.06
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 62% lower than other Healthcare stocks
[?] PE Ratio versus Industry 1496% higher than other Medical Care Facilities stocks
[?] Cash Yield 7.52%
[?] Free Cash Flow Jitter 85%

Insider Activity Summary

In the six months to 2026-11-22, no insider bought shares, and 11 insiders sold in 26 trades, about $51.8 million.

The six months before that had 0 buys and 8 sales.

Recent Insider Activity

Open-market buys and sells reported by Tenet Healthcare Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-11-11 Blunt Roy Sell 1,000 $293.00
2026-09-14 KERREY J ROBERT Sell 2,502 $264.62
2026-09-14 KERREY J ROBERT Sell 4,025 $264.10
2026-09-14 KERREY J ROBERT Sell 5,483 $263.04
2026-09-10 MARK RICHARD J Sell 10,000 $263.42
2026-09-02 West Nadja Sell 1,152 $258.80
2026-08-31 Foo Lisa Y (EVP, Chief Operating Officer) Sell 24,000 $266.32
2026-08-25 Sutaria Saumya (CEO) Sell 17,220 $273.34
2026-08-25 Sutaria Saumya (CEO) Sell 24,881 $274.10
2026-08-25 Sutaria Saumya (CEO) Sell 7,899 $275.26

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,775,956 shares shorted. With 78,768,244 shares available for purchase and an average trading volume over the past 10 trading days of 861,600, it would take at least 2.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 70318 208
2009 70318 425
2010 70318 472
2011 70318 380
2012 70318 398
2013 70318 256
2014 70318 168
2015 70318 338
2016 70318 -211
2017 70318 390
2018 70318 254
2019 70318 491
2020 70318 2,725
2021 70318 930
2022 70318 434
2023 70318 1,698
2024 70318 1,319
2025 70318 2,718

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 3 fiscal years from 2008 to 2010 with positive net income, operating cash flow totaled $1,105 million against net income of $1,325 million, or 0.83 times.

Cash conversion in 2010 was 0.42, below 0.80, so under 80% of reported net income arrived as operating cash. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 25 208 not reported 8.32
2009 181 425 not reported 2.35
2010 1,119 472 not reported 0.42

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 8 fiscal years from 2011 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $7,541 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 8 of the 8 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $3,448 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $1,386 million, 51.0% of estimated free cash flow of $2,718 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2011 380 n/a 374 374 98.4%
2012 398 n/a 126 126 31.6%
2013 256 n/a 400 400 156.1%
2015 338 n/a 40 40 11.8%
2022 434 n/a 250 250 57.7%
2023 1,698 n/a 200 200 11.8%
2024 1,319 n/a 672 672 51.0%
2025 2,718 n/a 1,386 1,386 51.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $19,621 million in 2016 and $21,310 million in 2025, a compound annual growth rate of 0.9% over 9 years.

Revenue rose 3.1% from 2024 to 2025.

Our estimated free cash flow was $2,718 million in 2025, 12.8% of revenue. In 2016 the estimated margin was negative 1.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 19,621 -211 -1.1%
2017 19,179 390 2.0%
2018 18,313 254 1.4%
2019 18,479 491 2.7%
2020 17,640 2,725 15.4%
2021 19,485 930 4.8%
2022 19,174 434 2.3%
2023 20,564 1,698 8.3%
2024 20,675 1,319 6.4%
2025 21,310 2,718 12.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $2,883 million against total liabilities of $17,748 million, or 16.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 59.8% of total assets in 2025, compared with 91.2% in 2009, a decrease of 31.4 percentage points.

Stockholders equity was $6,017 million in 2025, compared with $697 million in 2009, a rise of 763.3%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 12.2% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 7,953 690 7,256 697
2010 8,500 405 6,681 1,819
2011 8,462 113 6,954 1,492
2012 9,044 364 7,810 1,218
2013 16,450 113 15,232 878
2014 17,951 193 16,765 785
2015 23,682 356 20,458 958
2016 24,701 716 21,226 1,082
2017 23,385 611 21,036 539
2018 22,430 411 20,365 687
2019 23,365 262 21,422 437
2020 27,106 2,446 22,265 937
2021 27,579 2,364 21,119 2,054
2022 27,156 858 20,399 2,459
2023 28,312 1,228 20,413 3,117
2024 28,936 3,019 17,662 5,820
2025 29,677 2,883 17,748 6,017

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $263.19, our model's value equals that price if free cash flow grows an average of -0.8 percent a year over the 10 projection years. Our model assumes 3.1 percent a year for this stock, so the price implies growth of -0.8 percent, which is below the 3.1 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1,575 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $210.55 -4.8%
Current price $263.19 -0.8%
20 percent above the current price $315.83 2.2%
Our model (stored fair price) $332.57 3.1%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Only 17 of the 18 fiscal years under Tenet Healthcare Corporation's current filer show positive free cash flow.

The latest three years average $1,911 million in free cash flow against $368 million for the earliest three, which is a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 85%.

At $263.19, the stock is under our safe value of $266.06, against a fair value estimate of $332.57.

No dividend yield is recorded for Tenet Healthcare Corporation in our data.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 62% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 1496% above the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to Tenet Healthcare Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Tenet Healthcare Corporation (THC) 20,947 7.7 - 7.5% 21% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above
Universal Health Services (UHS) 10,345 7.5 0.5% 13.7% 71% below
DaVita (DVA) 10,129 12.2 - 14.7% 57% below
Surgery Partners (SGRY) 3,505 - - - 105% above
Progyny (PGNY) 2,630 32.8 - - 409% above
Healthcare Services Group (HCSG) 1,667 16.7 - 4.0% 17% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 70318.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: THC annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in THC

Does Tenet Healthcare Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: THC

This example shows how we apply the Trendshare checklist to THC: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 263.19
    • Market cap: $21B
    • EPS: 34.29
  2. Step 2 — Valuation checks

    • P/E: 7.675
    • FCF yield: 7.5%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.